Use the journals feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#61
JOURNAL ARTICLE
Rocío Paz-González, Vanesa Balboa-Barreiro, Lucia Lourido, Valentina Calamia, Patricia Fernandez-Puente, Natividad Oreiro, Cristina Ruiz-Romero, Francisco J Blanco
OBJECTIVE: Early diagnosis of knee osteoarthritis (KOA) in asymptomatic stages is essential for the timely management of patients using preventative strategies. We develop and validate a prognostic model useful for predicting the incidence of radiographic KOA (rKOA) in non-radiographic osteoarthritic subjects and stratify individuals at high risk of developing the disease. METHODS: Subjects without radiographic signs of KOA according to the Kellgren and Lawrence (KL) classification scale (KL=0 in both knees) were enrolled in the OA initiative (OAI) cohort and the Prospective Cohort of A Coruña (PROCOAC)...
April 11, 2024: Annals of the Rheumatic Diseases
#62
JOURNAL ARTICLE
Désirée van der Heijde, Anna Molto, Sofia Ramiro, Jürgen Braun, Maxime Dougados, Floris A van Gaalen, Lianne S Gensler, Robert D Inman, Robert B M Landewé, Helena Marzo-Ortega, Victoria Navarro-Compán, Andri Phoka, Denis Poddubnyy, Mikhail Protopopov, John Reveille, Martin Rudwaleit, Percival Sampaio-Barros, Alexandre Sepriano, Joachim Sieper, Filip E Van den Bosch, Irene van der Horst-Bruinsma, Pedro M Machado, Xenofon Baraliakos
Ankylosing spondylitis (AS) is the historic term used for decades for the HLA-B27-associated inflammatory disease affecting mainly the sacroiliac joints (SIJ) and spine. Classification criteria for AS have radiographic sacroiliitis as a dominant characteristic. However, with the availability of MRI of SIJ, it could be demonstrated that the disease starts long before definite SIJ changes become visible on radiographs. The Assessment of SpondyloArthritis international Society, representing a worldwide group of experts reached consensus on changes in the nomenclature pertaining to axial spondyloarthritis (axSpA), such as the terminology of diagnosis and of assessment of disease activity tools...
April 11, 2024: Annals of the Rheumatic Diseases
#63
RANDOMIZED CONTROLLED TRIAL
Max M H Teuwen, Salima F E van Weely, Thea P M Vliet Vlieland, Maria A T van Wissen, Wilfred F Peter, Alfons A den Broeder, Dirkjan van Schaardenburg, Wilbert B van den Hout, Cornelia H M Van den Ende, Maaike G J Gademan
OBJECTIVES: To compare the effectiveness of longstanding (>52 weeks), supervised exercise therapy with usual care in adults with rheumatoid arthritis (RA) and severe functional limitations. METHODS: Participants were randomised 1:1 to the intervention (individualised goal-setting, active exercises, education and self-management regarding physical activity) or usual care. Primary endpoint was the change in the Patient-Specific Complaints activity ranked 1 (PSC1, 0-10) at 52 weeks...
March 12, 2024: Annals of the Rheumatic Diseases
#64
JOURNAL ARTICLE
Joshua F Baker, James R ODell, Bryant R England, Jon T Giles, Jefferey A Newcomb, Michael D George, Geoffrey Thiele, Larry Moreland, S Louis Bridges, Jeffrey R Curtis, Ted R Mikuls
PURPOSE: To determine if body mass index (BMI) and adipokine levels identify rheumatoid arthritis (RA) patients most likely to benefit from initiation of tumour necrosis factor inhibitors (TNFi) after methotrexate inadequate response. METHODS: This is a secondary analysis of the Rheumatoid Arthritis Comparison of Active Treatments (RACAT) trial and the (TEAR) trial. Both studies compared treatment strategies starting with conventional disease-modifying anti-rheumatic drugs (DMARDs) (triple therapy) versus etanercept plus methotrexate...
March 12, 2024: Annals of the Rheumatic Diseases
#65
RANDOMIZED CONTROLLED TRIAL
Di Wu, Jing Li, Dong Xu, Joan T Merrill, Ronald F van Vollenhoven, Yi Liu, Jiankang Hu, Yang Li, Fen Li, Chenghui Huang, Guochun Wang, Xiaomei Li, Jianhong Zhao, Dongbao Zhao, Cibo Huang, Huaxiang Liu, Wei Wei, Guixiu Shi, Fuai Lu, Xiaoxia Zuo, Liqi Bi, Zhijun Li, Xiaoxia Wang, Miaojia Zhang, Ning Tie, Juan Li, Hanyou Mo, Jianmin Fang, Chunde Bao, Fengchun Zhang
OBJECTIVES: This phase 2b, randomised, double-blind, placebo-controlled trial evaluated the efficacy and safety of telitacicept, a novel fusion protein that neutralises signals of B lymphocyte stimulator and a proliferation-inducing ligand, in active systemic lupus erythematosus (SLE). METHODS: Adult patients with active SLE (n=249) were recruited from 29 hospitals in China and randomised 1:1:1:1 to receive subcutaneous telitacicept at 80 mg (n=62), 160 mg (n=63), 240 mg (n=62) or placebo (n=62) once weekly in addition to standard therapy...
March 12, 2024: Annals of the Rheumatic Diseases
#66
JOURNAL ARTICLE
Kevin L Winthrop, Philip Mease, Andreas Kerschbaumer, Reinhard E Voll, Ferdinand C Breedveld, Josef S Smolen, Jacques-Eric Gottenberg, Xenofon Baraliakos, Hans P Kiener, Daniel Aletaha, John D Isaacs, Maya H Buch, Mary K Crow, Jonathan Kay, Leslie Crofford, Ronald F van Vollenhoven, Caroline Ospelt, Stefan Siebert, Margreet Kloppenburg, Iain B McInnes, Tom Wj Huizinga, Ellen M Gravallese
The Advances in Targeted Therapies meets annually, convening experts in the field of rheumatology to both provide scientific updates and identify existing scientific gaps within the field. To review the major unmet scientific needs in rheumatology. The 23rd annual Advances in Targeted Therapies meeting convened with more than 100 international basic scientists and clinical researchers in rheumatology, immunology, infectious diseases, epidemiology, molecular biology and other specialties relating to all aspects of immune-mediated inflammatory diseases...
March 12, 2024: Annals of the Rheumatic Diseases
#67
JOURNAL ARTICLE
Fernanda Gutierrez-Rodrigues, Kristina V Wells, Adrianna I Jones, Dalton Hironaka, Cameron Rankin, Massimo Gadina, Keith A Sikora, Lemlem Alemu, Rodrigo T Calado, Kaitlin A Quinn, Bhavisha Patel, Neal S Young, Peter C Grayson
OBJECTIVES: Ageing and inflammation are associated with clonal haematopoiesis (CH), the emergence of somatic mutations in haematopoietic cells. This study details CH in patients with systemic vasculitis in association with clinical, haematological and immunological parameters. METHODS: Patients with three forms of vasculitis were screened for CH in peripheral blood by error-corrected sequencing. Relative contributions of age and vasculitis on CH prevalence were calculated using multivariable logistic regression...
March 12, 2024: Annals of the Rheumatic Diseases
#68
JOURNAL ARTICLE
Meng-Ko Tsai, Yen-Lin Chen, Hsiang-Cheng Chen, Feng-Cheng Liu, Deh-Ming Chang, Chun-Chi Lu
No abstract text is available yet for this article.
March 12, 2024: Annals of the Rheumatic Diseases
#69
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
February 15, 2024: Annals of the Rheumatic Diseases
#70
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
February 15, 2024: Annals of the Rheumatic Diseases
#71
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
February 15, 2024: Annals of the Rheumatic Diseases
#72
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
February 15, 2024: Annals of the Rheumatic Diseases
#73
RANDOMIZED CONTROLLED TRIAL
Reza Zonozi, Frank B Cortazar, Anushya Jeyabalan, Gabriel Sauvage, Pravarut Nithagon, Noah R Huizenga, Jillian M Rosenthal, Alexander Sipilief, Katherine Cosgrove, Karen A Laliberte, Eugene P Rhee, William F Pendergraft, John L Niles
OBJECTIVE: To compare two long-term remission maintenance strategies for antineutrophil cytoplasmic antibody (ANCA) vasculitis. METHODS: We conducted a prospective, single-centre, open-label, randomised controlled trial of patients with ANCA vasculitis in remission after completing at least 2 years of fixed-schedule rituximab. In the B cell arm, rituximab was reinfused upon B cell repopulation; in the ANCA arm, rituximab was reinfused upon significant rise in ANCA level...
February 15, 2024: Annals of the Rheumatic Diseases
#74
MULTICENTER STUDY
Benjamin de Valence, Marion Delaune, Yann Nguyen, Vincent Jachiet, Mael Heiblig, Alexis Jean, Stanislas Riescher Tuczkiewicz, Pierrick Henneton, Philippe Guilpain, Nicolas Schleinitz, Guillaume Le Guenno, Hervé Lobbes, Valentin Lacombe, Samuel Ardois, Estibaliz Lazaro, Vincent Langlois, Roderau Outh, Julien Vinit, Jean-Philippe Martellosio, Paul Decker, Thomas Moulinet, Yannick Dieudonné, Adrien Bigot, Louis Terriou, Alexandre Vlakos, Baptiste de Maleprade, Guillaume Denis, Jonathan Broner, Marie Kostine, Sebastien Humbert, Francois Lifermann, Maxime Samson, Susann Pechuzal, Achille Aouba, Olivier Kosmider, Jeremie Dion, Sylvie Grosleron, Rim Bourguiba, Benjamin Terrier, Sophie Georgin-Lavialle, Olivier Fain, Arsène Mekinian, Marjolaine Morgand, Thibault Comont, Jerome Hadjadj
INTRODUCTION: Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome is an acquired autoinflammatory monogenic disease with a poor prognosis whose determinants are not well understood. We aimed to describe serious infectious complications and their potential risk factors. METHODS: Retrospective multicentre study including patients with VEXAS syndrome from the French VEXAS Registry. Episodes of serious infections were described, and their risk factors were analysed using multivariable Cox proportional hazards models...
February 15, 2024: Annals of the Rheumatic Diseases
#75
JOURNAL ARTICLE
Eleftheria Pertsinidou, Saedis Saevarsdottir, Vivek Anand Manivel, Lars Klareskog, Lars Alfredsson, Linda Mathsson-Alm, Monika Hansson, Martin Cornillet, Guy Serre, Rikard Holmdahl, Karl Skriner, Per-Johan Jakobsson, Helga Westerlind, Johan Askling, Johan Rönnelid
OBJECTIVES: To investigate how individual rheumatoid arthritis (RA) autoantibodies associate with individual signs and symptoms at the time of RA diagnosis. METHODS: IgA, IgG, IgM rheumatoid factor (RF), antibodies against cyclic citrullinated peptide version 2 (anti-CCP2) and 16 individual antibodies against citrullinated protein (ACPA) reactivities were analysed centrally in baseline sera from 1600 patients with RA classified according to the 1987 American College of Rheumatology (ACR) criteria...
February 15, 2024: Annals of the Rheumatic Diseases
#76
JOURNAL ARTICLE
David Moulin, Marie Millard, Mahdia Taïeb, Chloé Michaudel, Anne Aucouturier, Antoine Lefèvre, Luis G Bermúdez-Humarán, Philippe Langella, Youssouf Sereme, Kristell Wanherdrick, Preeti Gautam, Xavier Mariette, Philippe Dieudé, Jacques-Eric Gottenberg, Jean-Yves Jouzeau, David Skurnik, Patrick Emond, Denis Mulleman, Jérémie Sellam, Harry Sokol
OBJECTIVES: Alterations in tryptophan (Trp) metabolism have been reported in inflammatory diseases, including rheumatoid arthritis (RA). However, understanding whether these alterations participate in RA development and can be considered putative therapeutic targets remains undetermined.In this study, we combined quantitative Trp metabolomics in the serum from patients with RA and corrective administration of a recombinant enzyme in experimental arthritis to address this question. METHODS: Targeted quantitative Trp metabolomics was performed on the serum from 574 previously untreated patients with RA from the ESPOIR (Etude et Suivi des POlyarthrites Indifférenciées Récentes) cohort and 98 healthy subjects...
February 15, 2024: Annals of the Rheumatic Diseases
#77
JOURNAL ARTICLE
Hilde Julie T Lien, Tina T Pedersen, Bente Jakobsen, Arnar Flatberg, Konika Chawla, Pål Sætrom, Mona H Fenstad
OBJECTIVES: Comparative longitudinal analyses of cellular composition and peripheral blood gene expression in Rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and healthy pregnancies. METHODS: In total, 335 whole blood samples from 84 RA, SLE and healthy controls before pregnancy, at each trimester, 6 weeks, 6 months and 12 months post partum were analysed. We combined bulk and single cell RNA analyses for cell-type estimation, validated by flow cytometry, before combining this in a cell-type adjusted analysis for an improved resolution of unrecognised gene expression changes associated with RA and SLE pregnancies...
February 15, 2024: Annals of the Rheumatic Diseases
#78
JOURNAL ARTICLE
Doruk Erkan, Medha Barbhaiya, Stephane Zuily, Maria Laura Bertolaccini, Rohan Willis, Katrien Devreese
No abstract text is available yet for this article.
February 15, 2024: Annals of the Rheumatic Diseases
#79
JOURNAL ARTICLE
Susan Bridgewater, Mwidimi Ndosi, Jill Dawson, Pamela Richards, Christine Silverthorne, Emma Dures, Susan M Goodman, Catherine Hill, Sarah L Mackie, Joanna C Robson
OBJECTIVES: Glucocorticoids used in the treatment of inflammatory rheumatic conditions can impact on health-related quality of life. An underpinning qualitative study developed a long-list of candidate items for a treatment-specific patient-reported outcome (PRO) measure. The objective of this paper is to determine scale structure and psychometric properties of the Steroid PRO. METHODS: A cross-sectional survey of adults from the UK, USA, Australia and New Zealand, taking glucocorticoids for a rheumatic disease...
February 15, 2024: Annals of the Rheumatic Diseases
#80
LETTER
Mathilde Pezot, Gaétane Nocturne, Rakiba Belkhir, Julien Henry, Stephan Pavy, Raphaèle Seror, Xavier Mariette, Samuel Bitoun
No abstract text is available yet for this article.
February 15, 2024: Annals of the Rheumatic Diseases
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
